NCT06160401 is a Phase 1 clinical trial of Singletine in Healthy Subjects, sponsored by Guangzhou JOYO Pharma Co., Ltd.

Who is sponsoring NCT06160401?

NCT06160401 is sponsored by Guangzhou JOYO Pharma Co., Ltd.

What drugs are being tested in NCT06160401?

Interventions in NCT06160401: Singletine, Placebo.

What condition does NCT06160401 study?

NCT06160401 studies Healthy Subjects.

Is NCT06160401 still recruiting?

NCT06160401 is currently completed. Last updated 7 December 2023.

Last reviewed 2023-12-07 · How we verify

NCT06160401

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Safety, Tolerability, PK/PD, and Metabolism of Single-Dose Singletine(DC407) in Adults

Completed Phase 1 Last updated 7 December 2023

What this trial tests

Phase 1 trial testing Singletine in Healthy Subjects in 75 participants. Completed in 30 January 2021.

Timeline

18 August 2020

Primary endpoint
30 January 2021

30 January 2021

Quick facts

Lead sponsor	Guangzhou JOYO Pharma Co., Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	75
Start date	18 August 2020
Primary completion	30 January 2021
Estimated completion	30 January 2021
Sites	1 location across China

Drugs / interventions tested

Singletine — full drug profile →
Placebo

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Guangzhou JOYO Pharma Co., Ltd — full company profile →

Who can join

Adults 18 to 45, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetic characteristics of Singletine in healthy adult subjects. The main questions it aims to answer are: safety and tolerability of Singletine in healthy subjects, the pharmacokinetic characteristics after single and multiple doses and the effect of food on the pharmacokinetic characteristics. Participants will be treated with Singletine orally and safety and pharmacokinetic evaluations will be conducted according to the protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Guangzhou JOYO Pharma Co., Ltd trials

Trials by the same sponsor.

NCT07154368 — JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. · Phase 3 · not yet recruiting
NCT06895031 — Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS · Phase 2 · recruiting
NCT06158490 — A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis · Phase 2 · enrolling by invitation
NCT06125327 — SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2, PHASE3 · recruiting
NCT06697535 — A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06160401 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou JOYO Pharma Co., Ltd
Last refreshed: 7 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06160401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing